Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Targeting low molecular weight cyclin E (LMW-E) in breast cancer.

Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, Galons H, Joseph B, Meijer L, Hunt KK, Keyomarsi K.

Breast Cancer Res Treat. 2012 Apr;132(2):575-88. doi: 10.1007/s10549-011-1638-4. Epub 2011 Jun 22.

2.

LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.

Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K.

PLoS Genet. 2012;8(3):e1002538. doi: 10.1371/journal.pgen.1002538. Epub 2012 Mar 29.

3.

Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.

Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K.

Clin Cancer Res. 2010 Feb 15;16(4):1179-90. doi: 10.1158/1078-0432.CCR-09-1787. Epub 2010 Feb 9.

4.

Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.

Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K.

Cancer Res. 2004 May 1;64(9):3198-208.

5.

Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.

Duong MT, Akli S, Macalou S, Biernacka A, Debeb BG, Yi M, Hunt KK, Keyomarsi K.

Cancer Res. 2013 Sep 1;73(17):5556-68. doi: 10.1158/0008-5472.CAN-13-0013. Epub 2013 Aug 16.

6.

Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.

Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K.

Cancer Res. 2011 May 1;71(9):3377-86. doi: 10.1158/0008-5472.CAN-10-4086. Epub 2011 Mar 8.

7.

Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression.

Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, Tucker SL, Van Pelt C, Meijer L, Hunt K, Keyomarsi K.

Cell Cycle. 2009 Apr 1;8(7):1062-8. Epub 2009 Apr 10.

8.

Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.

Bagheri-Yarmand R, Nanos-Webb A, Biernacka A, Bui T, Keyomarsi K.

Cancer Res. 2010 Jun 15;70(12):5085-95. doi: 10.1158/0008-5472.CAN-09-4095. Epub 2010 Jun 8.

9.

Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification.

Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K.

Cancer Res. 2010 Jun 15;70(12):5074-84. doi: 10.1158/0008-5472.CAN-09-4094. Epub 2010 Jun 8.

10.

The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.

Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K.

J Biol Chem. 2005 Apr 15;280(15):15148-57. Epub 2005 Feb 10.

11.

Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.

Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, DiRenzo J, Greninger P, Sharma SV, Settleman J, Compton DA, Dmitrovsky E.

Clin Cancer Res. 2010 Jan 1;16(1):109-20. doi: 10.1158/1078-0432.CCR-09-2151. Epub 2009 Dec 22.

12.

A novel interaction between HER2/neu and cyclin E in breast cancer.

Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK.

Oncogene. 2010 Jul 8;29(27):3896-907. doi: 10.1038/onc.2010.151. Epub 2010 May 10.

13.

Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation.

Delk NA, Hunt KK, Keyomarsi K.

Cancer Res. 2009 Apr 1;69(7):2817-25. doi: 10.1158/0008-5472.CAN-08-4182. Epub 2009 Mar 24.

14.

Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines.

Cooley A, Zelivianski S, Jeruss JS.

Cell Cycle. 2010 Dec 15;9(24):4900-7. Epub 2010 Dec 15.

15.

The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells.

Wingate H, Bedrosian I, Akli S, Keyomarsi K.

Cell Cycle. 2003 Sep-Oct;2(5):461-6.

PMID:
12963845
16.

Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.

Appleyard MV, O'Neill MA, Murray KE, Paulin FE, Bray SE, Kernohan NM, Levison DA, Lane DP, Thompson AM.

Int J Cancer. 2009 Jan 15;124(2):465-72. doi: 10.1002/ijc.23938.

17.

Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.

Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K.

Cancer Res. 2007 Aug 1;67(15):7212-22.

18.

Why are the truncated cyclin Es more effective CDK2 activators than the full-length isoforms?

Rath SL, Senapati S.

Biochemistry. 2014 Jul 22;53(28):4612-24. doi: 10.1021/bi5004052. Epub 2014 Jul 10.

PMID:
24947816
19.

Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death.

Josefsberg Ben-Yehoshua L, Beider K, Shimoni A, Ostrovsky O, Samookh M, Peled A, Nagler A.

PLoS One. 2012;7(4):e33856. doi: 10.1371/journal.pone.0033856. Epub 2012 Apr 25.

20.

Low-molecular-weight cyclin E: the missing link between biology and clinical outcome.

Akli S, Keyomarsi K.

Breast Cancer Res. 2004;6(5):188-91. Epub 2004 Jul 7.

Supplemental Content

Support Center